Related Experiment Video
Updated: Jun 25, 2026
09:02
Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
Published on: July 31, 2016
[Pelvic perfusion for localy advanced tumors]
Sylvie Bonvalot1, Jane Muret, Thierry Debaere
1Département de chirurgie, Institut Gustave-Roussy, 39, rue Camille-Desmoulins, 94805 Villejuif. bonvalot@igr.fr
Bulletin Du Cancer
|February 13, 2009
Summary
Isolated pelvic perfusion (IPP) offers high-dose pelvic cancer treatment with minimal side effects. An improved technique enhances drug delivery, showing promise for advanced cancers previously untreatable by conventional methods.
Area of Science:
- Oncology
- Surgical Oncology
- Pharmacology
Context:
- Isolated pelvic perfusion (IPP) is an intra-arterial treatment method.
- A simplified balloon occlusion technique is employed.
- Recent advancements include using a pressure-suit for improved drug distribution.
Purpose:
- To evaluate an improved isolated pelvic perfusion (IPP) technique.
- To assess the efficacy of IPP with TNF-alpha and melphalan for advanced pelvic cancers.
- To compare IPP outcomes with conventional chemo-radiation and isolated limb perfusions.
Summary:
- The enhanced IPP technique utilizes a pressure-suit to improve the ratio between pelvic and systemic drug distribution.
- This method achieves high-dose drug concentration in the pelvis with minimal adverse effects.
- The stop-flow technique with low-dose TNF-alpha and melphalan shows promise in palliating advanced cancers, improving resectability in patients ineligible for conventional treatments.
Impact:
- Demonstrates a promising alternative for treating advanced pelvic cancers.
- Offers a potentially more effective and less toxic treatment option compared to conventional therapies.
- Provides a basis for a forthcoming randomized study to further validate its efficacy.
